FY2025 Earnings Forecast for Cytokinetics Issued By B. Riley

Cytokinetics, Incorporated (NASDAQ:CYTK) – Research analysts at B. Riley upped their FY2025 earnings per share estimates for shares of Cytokinetics in a research note issued to investors on Monday, November 10th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of ($5.63) per share for the year, up from their prior estimate of ($5.72). B. Riley currently has a “Buy” rating and a $90.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q4 2025 earnings at ($1.60) EPS, FY2026 earnings at ($6.47) EPS, FY2027 earnings at ($5.81) EPS, FY2028 earnings at ($3.52) EPS and FY2029 earnings at $0.41 EPS.

Several other equities analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $120.00 price objective on shares of Cytokinetics in a research note on Monday, September 29th. Evercore ISI boosted their price target on shares of Cytokinetics from $60.00 to $80.00 and gave the company an “outperform” rating in a research report on Wednesday, September 3rd. Needham & Company LLC reissued a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a research report on Tuesday, September 2nd. Bank of America raised their price objective on Cytokinetics from $52.00 to $56.00 and gave the company a “neutral” rating in a research report on Thursday, October 2nd. Finally, Royal Bank Of Canada upped their price objective on shares of Cytokinetics from $82.00 to $87.00 and gave the stock an “outperform” rating in a report on Tuesday. Thirteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $77.86.

Cytokinetics Stock Up 6.9%

NASDAQ:CYTK opened at $66.50 on Wednesday. The firm has a market capitalization of $8.13 billion, a P/E ratio of -13.04 and a beta of 0.58. Cytokinetics has a 52 week low of $29.31 and a 52 week high of $66.72. The company has a fifty day moving average of $56.14 and a 200 day moving average of $42.47.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.59) by $0.05. The company had revenue of $1.94 million during the quarter, compared to analysts’ expectations of $6.05 million. Cytokinetics’s revenue for the quarter was up 318.1% on a year-over-year basis. During the same period last year, the firm earned ($1.36) earnings per share.

Hedge Funds Weigh In On Cytokinetics

A number of institutional investors and hedge funds have recently modified their holdings of CYTK. Norges Bank bought a new position in Cytokinetics in the second quarter valued at about $39,122,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. grew its position in shares of Cytokinetics by 571.2% during the 2nd quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 1,082,563 shares of the biopharmaceutical company’s stock valued at $35,768,000 after acquiring an additional 921,278 shares during the period. Paradigm Biocapital Advisors LP purchased a new stake in shares of Cytokinetics in the 1st quarter worth $34,510,000. Jennison Associates LLC purchased a new position in Cytokinetics during the first quarter valued at $27,085,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in Cytokinetics during the second quarter valued at about $18,328,000.

Insiders Place Their Bets

In other news, Director Edward M. Md Kaye sold 6,757 shares of the business’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $60.00, for a total transaction of $405,420.00. Following the completion of the transaction, the director directly owned 9,778 shares of the company’s stock, valued at $586,680. The trade was a 40.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Fady Ibraham Malik sold 2,295 shares of the firm’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $59.55, for a total transaction of $136,667.25. Following the completion of the sale, the executive vice president owned 140,610 shares in the company, valued at $8,373,325.50. This represents a 1.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 56,983 shares of company stock worth $3,165,356 in the last 90 days. Corporate insiders own 2.70% of the company’s stock.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.